Trevena, Inc. – NASDAQ:TRVN
Trevena stock price today
$0.275
-1.41
-83.73%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 14 hours
Trevena stock price monthly change
+600.95%
month
Trevena stock price quarterly change
+600.95%
quarter
Trevena stock price yearly change
+141.77%
year
Trevena key metrics
Market Cap | 1.52M |
Enterprise value | N/A |
P/E | -0.08 |
EV/Sales | -1633.77 |
EV/EBITDA | 1.05 |
Price/Sales | 237.27 |
Price/Book | 0.30 |
PEG ratio | N/A |
EPS | -2.67 |
Revenue | 3.14M |
EBITDA | -34.20M |
Income | -40.13M |
Revenue Q/Q | 233.33% |
Revenue Y/Y | N/A |
Profit margin | -157118.35% |
Oper. margin | -156646.87% |
Gross margin | -2030.09% |
EBIT margin | -156646.87% |
EBITDA margin | -1089.33% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeTrevena stock price history
Trevena stock forecast
Trevena financial statements
| Jun 2023 | 3.02M | -8.01M | -265.21% |
|---|---|---|---|
| Sep 2023 | 180K | -7.93M | -4405.56% |
| Dec 2023 | -81K | -16.51M | 20382.72% |
| Mar 2024 | 20K | -7.67M | -38390% |
| Dec 2023 | -81K | -16.51M | 20382.72% |
|---|---|---|---|
| Mar 2024 | 20K | -7.67M | -38390% |
| Oct 2025 | 8.07K | -4.47M | -55415.73% |
| Dec 2025 | 3M | -2.34M | -78.11% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 38859000 | 29.07M | 74.83% |
|---|---|---|---|
| Sep 2023 | 45133000 | 41.58M | 92.14% |
| Dec 2023 | 40605000 | 48.26M | 118.86% |
| Mar 2024 | 31137000 | 45.79M | 147.06% |
| Jun 2023 | -7.25M | -20K | 6.50M |
|---|---|---|---|
| Sep 2023 | -8.92M | 0 | 15.78M |
| Dec 2023 | -5.98M | -21K | 4.02M |
| Mar 2024 | -9.42M | 0 | -3K |
Trevena alternative data
| Aug 2023 | 35 |
|---|---|
| Sep 2023 | 35 |
| Oct 2023 | 35 |
| Nov 2023 | 35 |
| Dec 2023 | 35 |
| Jan 2024 | 35 |
| Feb 2024 | 35 |
| Mar 2024 | 35 |
| Apr 2024 | 35 |
| May 2024 | 35 |
| Jun 2024 | 23 |
| Jul 2024 | 23 |
Trevena other data
11.28%
-1.66%
of TRVN is owned by hedge funds
46
-19
747.07K
-110.06K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jun 2022 | 0 | 31785 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | SHIN BARRY officer: SVP, CFO | Common Stock | 31,785 | $0.41 | $13,032 | ||
Purchase | BOURDOW CARRIE L. director, officer.. | Common Stock | 56,200 | N/A | N/A | ||
Purchase | HAMILL JOHN P. officer: VP Fin,P.. | Common Stock | 7,500 | N/A | N/A | ||
Purchase | HAMILL JOHN P. officer: VP Fin,P.. | Common Stock | 7,500 | N/A | N/A | ||
Purchase | MOULDER LEON O JR director | Common Stock | 100,000 | N/A | N/A | ||
Purchase | GOWEN MAXINE director | Common Stock | 50,000 | N/A | N/A | ||
Sale | HABIB YACOUB officer: SVP, Bus Dev & Corp Pl.. | Common Stock | 5,000 | N/A | N/A | ||
Option | GOWEN MAXINE director | Employee Stock Option (Right to Buy) | 4,074 | N/A | N/A | ||
Option | GOWEN MAXINE director | Common Stock | 110,403 | N/A | N/A | ||
Option | LARK MICHAEL W. officer: Sr. VP, Research & CSO | Employee Stock Option (Right to Buy) | 12,815 | N/A | N/A |
| Patent |
|---|
Application Filling date: 2 Jul 2021 Issue date: 9 Jun 2022 |
Grant Utility: 7-membered aza-heterocyclic containing .delta.-opioid receptor modulating compounds, methods of using and making the same Filling date: 15 Feb 2018 Issue date: 18 Jan 2022 |
Application Filling date: 20 Apr 2021 Issue date: 21 Oct 2021 |
Grant Filling date: 1 Dec 2017 Issue date: 3 Aug 2021 |
Application Filling date: 12 Jun 2018 Issue date: 24 Jun 2021 |
Application Filling date: 17 Nov 2020 Issue date: 20 May 2021 |
Application 7-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME Filling date: 15 Feb 2018 Issue date: 4 Mar 2021 |
Application 5-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME Filling date: 15 Feb 2018 Issue date: 4 Mar 2021 |
Application Filling date: 26 Feb 2020 Issue date: 28 Jan 2021 |
Application 6-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME Filling date: 27 Feb 2019 Issue date: 23 Jul 2020 |
| Quarter | Transcript |
|---|---|
| Q3 2023 14 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q1 2023 15 May 2023 | Q1 2023 Earnings Call Transcript |
| Q4 2022 31 Mar 2023 | Q4 2022 Earnings Call Transcript |
| Q3 2022 13 Nov 2022 | Q3 2022 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Ms. Carrie L. Bourdow (1963) Pres, Chief Executive Officer & Director | $1,140,000 |
| Dr. Mark A. Demitrack (1958) Senior Vice President & Chief Medical Officer | $725,670 |
Trevena Offers An Enticing Risk-Reward At These Prices
Trevena: Remaining Patient After A Disappointing Q2 Earnings
Week In Review: Keymed Completes $378 Million IPO In Hong Kong For Antibody Drugs
Trevena's OLINVYK Provides One Of The Most Compelling Growth Profiles
Trevena: Taking A Systematic Approach With A Speculative Investment
-
What's the price of Trevena stock today?
One share of Trevena stock can currently be purchased for approximately $0.28.
-
When is Trevena's next earnings date?
Unfortunately, Trevena's (TRVN) next earnings date is currently unknown.
-
Does Trevena pay dividends?
No, Trevena does not pay dividends.
-
How much money does Trevena make?
Trevena has a market capitalization of 1.52M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 847.61% to 3.13M US dollars.
-
What is Trevena's stock symbol?
Trevena, Inc. is traded on the NASDAQ under the ticker symbol "TRVN".
-
What is Trevena's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Trevena?
Shares of Trevena can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Trevena's key executives?
Trevena's management team includes the following people:
- Ms. Carrie L. Bourdow Pres, Chief Executive Officer & Director(age: 62, pay: $1,140,000)
- Dr. Mark A. Demitrack Senior Vice President & Chief Medical Officer(age: 67, pay: $725,670)
-
How many employees does Trevena have?
As Jul 2024, Trevena employs 23 workers, which is 34% less then previous quarter.
-
When Trevena went public?
Trevena, Inc. is publicly traded company for more then 11 years since IPO on 31 Jan 2014.
-
What is Trevena's official website?
The official website for Trevena is trevena.com.
-
Where are Trevena's headquarters?
Trevena is headquartered at 955 Chesterbrook Boulevard, Chesterbrook, PA.
-
How can i contact Trevena?
Trevena's mailing address is 955 Chesterbrook Boulevard, Chesterbrook, PA and company can be reached via phone at +61 3548840.
Trevena company profile:
Trevena, Inc.
trevena.comExchange:
NASDAQ
Full time employees:
23
Industry:
Biotechnology
Sector:
Healthcare
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
955 Chesterbrook Boulevard
Chesterbrook, PA 19087
Chesterbrook, PA 19087
CIK: 0001429560
ISIN: US89532E2081
CUSIP: 89532E109
